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Ending the Global Tuberculosis Epidemic by 2030 — The Moscow
Declaration and achieving a Major Translational Change in Delivery of
TB Healthcare
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journal homepage: www.elsevier .com/ locate / i j idAccording to the latest WHO Annual Global TB Report
(WHO, 2017a), Tuberculosis (TB) remains the world’s top infectious
diseases cause of death, being responsible for an estimated
1.674.000 deaths worldwide in 2016. Alarmingly, there were
600.000 cases of rifampicin-resistant TB of which 490.000 had
multidrug-resistant TB (MDR-TB). Less than 50% of these patients
survive after receiving currently recommended WHO treatment
regimens, illustrating the dire state of current global TB control
efforts. The ﬁrst WHO Global Ministerial Conference “Ending
Tuberculosis in the Sustainable Development Era: A Multisectoral
Response”, was held in Moscow, the Russian Federation, on 17th
November 2017. Ministers from 75 countries agreed on the
“Moscow Declaration” (WHO, 2017d) committing to urgent action
to fulﬁll the WHO “End Tuberculosis” strategy by 2030
(WHO, 2017b). It also commits to increasing multisectoral action,
tracking progress, and ensuring accountability. The Moscow
declaration will inform the ﬁrst UN General Assembly High-Level
Meeting on TB to be held in New York in September 2018 to
generate further commitments from member states.
Key sentences in the declaration read:
“Universal health coverage, sustainable ﬁnancing for multisectoral
action, rapid scale up of innovative approaches and tools, and
discovery of new and better tools for prevention, diagnosis and
treatment of TB will be fundamental to transform the ﬁght.
We also recognize the urgent need for committing immediate,
intensiﬁed, innovative and multisectoral actions to rapidly
accelerate progress in both research and implementation”.
Thus fulﬁllment of the laudable vision of the Moscow
Declaration will require a major translational transformation of
health care systems in TB endemic countries, substantial
investments in infrastructure, staff and staff education, laboratory
facilities and availability of drugs.
The Moscow Declaration argues that it is only by broadly
investing in health and ensuring that health care is accessible to all,
that we can reach the “End Tuberculosis” goal of having less than 1
case per million inhabitants by 2030 (WHO, 2017c), and speak
about “universal health coverage”. Thus the End-TB Strategy is not
a new vertical program but a horizontal effort to strengthen health
care overall and expand coverage. Implementing the Moscow
Declaration will require an overall strengthening of health care
systems with more facilities, staff, laboratories, diagnostics andhttps://doi.org/10.1016/j.ijid.2017.11.029
1201-9712/© 2017 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).treatment availability and will beneﬁt other areas for instance the
ﬁght against diabetes, malaria and HIV.
The interrelationship between TB and HIV remains a high
priority for TB control. Not all countries recognize and openly
acknowledge the HIV epidemic and public campaigns to inform
about risk factors are in some countries against religious beliefs.
Therefore to fulﬁll the End-TB Strategy the HIV epidemic need to be
addressed. For instance the Middle East, — a generalization and
may not apply to the region as a whole and wont be well received-
is there a better way to phrase? with a rapidly growing and young
population, has the fastest increase in new HIV cases world wide
(Gökengin et al., 2016). Integration of health care providing for HIV
and TB must be a priority and in donor- funded programs, for
instance by the Global Fund to Fight AIDS, Tuberculosis and
Malaria, funding should be made provisional on the merging of TB
and HIV programs (Linguissi et al., 2017). In countries where the
HIV epidemic is the major risk factor for new TB infections, and
reactivation of latent foci, timeous access to antiretroviral therapy
is critical.
There are approximately 2 billion people in the world with
latent TB infection (LTBI) who remain completely asymptomatic.
Many of these persons harbor viable Mycobacterium tuberculosis
bacteria. Between 5% to 15% will progress to develop active TB
disease during their lifetime due to a range of risk factors. Apart
from poverty and homelessness, HIV infection and immunosup-
pression due to other diseases and treatment are potent causes and
continue to fuel the TB epidemic. The number of people with LTBI is
approximately ten times the numbers with active TB, estimated at
10.4 million people (90% adults; 65% male; 10% people living with
HIV) (WHO World TB Report 2017). With a conservative estimate of
5% of people with LTBI progressing to developing active TB,
approximately 100 million people with risk factors will develop
active TB. In order to achieve the long term strategy of TB control
and fulﬁll the End-TB Strategy, people with LTBI at risk of
developing active TB must be identiﬁed and treated. Since
tuberculin skin tests are neither speciﬁc or sensitive, the WHO
recommended interferon-gamma release assays, (IGRAs), which
have sensitivities of between 84–95% and speciﬁcities of 85–99%
should be made available not only in high-risk communities in the
western countries but more widely in high TB endemic countries,
starting initially with speciﬁc high risk groups such as people living
with HIV, prisoners and school children. Individuals identiﬁed withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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for fully susceptible TB or 3 months of weekly isoniazid and
rifapentine (Zenner et al., 2017).
With no effective TB vaccine available (Kaufmann et al., 2017a,
b) the current emphasis on developing more effective treatment
regimens with two new TB drugs bedaquiline and delamanid
rolled out to all cases of MDR-TB becomes important. The vaccine
issue is not related to MDRTB Rx. However, the cost of these drugs
is a major barrier to their use. A recent study estimated the cost of
generic bedaquiline at US$8-$17/month and for generic delamanid
$5-$16/month (Gotham et al., 2017). Estimated generic prices were
$168-$395 per course for the STREAM trial modiﬁed Bangladesh
regimens (current costs $734-$1799), $53-$276 for pretomanid-
based three-drug regimens and $238-$507 for a delamanid-based
four-drug regimen (Gotham et al., 2017).
As rightly pointed out in the Moscow declaration, TB is no doubt
closely related to poor socio-economic conditions (Grange and
Zumla, 1999; Fineberg and Wilson, 1996). The signiﬁcant decline in
the incidence over time in the industrially developed nations in the
last century have been attributed to improved nutrition, housing
and socio-economic factors and occurred well before the
introduction of TB drugs (Grange et al., 2001; Zumla et al.,
2009). Implementing the Moscow Declaration will require a major
uplift of entire health care systems which can reach out to
marginalized populations both regards to ﬁnding the millions of
‘missing’ cases (Herbert et al., 2014), diagnosing them and more
importantly ensuring long term follow up to ensure compliance to
prevent occurrence of multi-drug resistant MDRTB. In order to
reach disadvantaged groups, active engagement with marginalized
groups like prisoners, drug users, migrants and refugees will be
needed. This can only be done by investing in community workers,
who can actively engage and build trust with these communities.
Mobile teams need to be developed, trained and equipped. All
these activities will require substantial increase in national and
donor funding.
To achieve the goals of the WHO End-TB Strategy and for follow
up on the Moscow Declaration, international donors will need to
increase their ﬁnancial support for health care systems focused on
poverty related diseases in developing countries with more
funding than current investments. It is therefore of concern thatthe administration in one of the biggest donors of international aid
for TB and HIV, the United States, is heading towards reduction in
foreign aid spending (even though foreign aid comprise roughly 1%
of the US state budget) (Brookings Institute, 2017). Therefore it
seems inevitable that all countries even with the lowest gross
domestic product, GDP, must now focus on ﬁnding the shortfall
and become self dependent. In this context it is disturbing to see
the spatial-temporal relationship between the Corruption Percep-
tions Index (Transparency International, 2016) and the annual
incidence of TB in countries (Figure 1). The recent increase in
political will to end the TB epidemic and engagement of a global
caucus of Parliamentarians from across all continents (Herbert
et al., 2017) is a welcome development and provides new hope for
getting national governments in high TB endemic countries to be
more transparent and committed, and ﬁnd ways of investing more
in TB control activities, and for western donors to increase their
contributions for achieving the EndTB goals.
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